Structures by: Nangia A.
Total: 676
C13H11N3O4S2,C6H6O2
C13H11N3O4S2,C6H6O2
Crystal Growth & Design (2013) 13, 5 1988
a=9.1170(10)Å b=9.8388(12)Å c=11.4240(12)Å
α=106.074(10)° β=90.432(9)° γ=93.503(10)°
C13H11N3O4S2,C7H6O3
C13H11N3O4S2,C7H6O3
Crystal Growth & Design (2013) 13, 5 1988
a=9.2338(11)Å b=11.074(2)Å c=11.864(2)Å
α=114.225(17)° β=95.085(12)° γ=104.375(13)°
1:1 cocrystal of Temozolomide and Caffeine
C6H6N6O2,C8H10N4O2
Crystal Growth & Design (2013) 13, 5 2208
a=8.698(3)Å b=9.187(3)Å c=12.231(4)Å
α=73.87(3)° β=87.42(3)° γ=64.52(3)°
2:1 cocrystal of Temozolomide and Isonicotinamide
2(C6H6N6O2),C6H6N2O
Crystal Growth & Design (2013) 13, 5 2208
a=9.645(3)Å b=10.609(3)Å c=10.925(3)Å
α=87.125(5)° β=75.546(4)° γ=87.003(4)°
2:1 cocrystal of Temozolomide and 4-hydroxybenzamide
2(C6H6N6O2),C7H7NO2
Crystal Growth & Design (2013) 13, 5 2208
a=9.834(3)Å b=10.797(3)Å c=11.809(3)Å
α=107.047(4)° β=101.419(4)° γ=101.835(4)°
1:1 cocrystal of Temozolomide and Pyrazinamide
C6H6N6O2,C5H5N3O
Crystal Growth & Design (2013) 13, 5 2208
a=8.5570(11)Å b=9.2537(12)Å c=10.3924(14)Å
α=68.398(2)° β=89.951(2)° γ=63.129(2)°
2:1 cocrystal of Temozolomide and 4-hydroxybenzaamide
2(C6H6N6O2),C7H7NO2
Crystal Growth & Design (2013) 13, 5 2208
a=6.9091(17)Å b=12.3493(19)Å c=14.141(2)Å
α=106.389(13)° β=92.948(16)° γ=100.942(17)°
C10H26Cl2N2O2
C10H26Cl2N2O2
Crystal Growth & Design (2013) 13, 4 1752
a=6.432(2)Å b=22.966(9)Å c=5.0934(19)Å
α=90.00° β=90.00° γ=90.00°
C10H24N2O2
C10H24N2O2
Crystal Growth & Design (2013) 13, 4 1752
a=7.1428(3)Å b=8.4149(3)Å c=10.1973(4)Å
α=90.00° β=95.633(4)° γ=90.00°
2:1 cocrystal of Temzolomide and Saccharin
2(C6H6N6O2),C7H5NO3S
Crystal Growth & Design (2013) 13, 5 2208
a=6.521(3)Å b=8.064(4)Å c=11.952(5)Å
α=76.591(7)° β=75.856(7)° γ=87.095(7)°
3-Aminopyridinium 3,5-dimethyl-4-hydroxybenzoate
C9H9O3.C5H7N2
Crystal Growth & Design (2009) 9, 3 1546
a=11.5274(12)Å b=11.9967(12)Å c=10.7001(11)Å
α=90.00° β=111.328(2)° γ=90.00°
4-Aminopyridinium 3-chloro-4-hydroxybenzoate hydrate
C7H4ClO3.C5H7N2.2(H2O)
Crystal Growth & Design (2009) 9, 3 1546
a=7.9596(10)Å b=9.2141(12)Å c=10.1006(13)Å
α=83.020(2)° β=78.551(2)° γ=88.151(1)°
4-Aminopyridinium 3-flouro-4-hydroxybenzoate hydrate
C7H4FO3.C5H7N2.H2O
Crystal Growth & Design (2009) 9, 3 1546
a=7.1711(7)Å b=12.8232(13)Å c=13.2749(14)Å
α=90.00° β=95.314(2)° γ=90.00°
3-Aminopyridinium 3-flouro-4-hydroxybenzoate
C7H4O3F.C5H7N2
Crystal Growth & Design (2009) 9, 3 1546
a=12.0905(16)Å b=9.0847(12)Å c=12.0905(16)Å
α=90.00° β=118.30° γ=90.00°
3-Aminopyridinium 4-hydroxybenzoate
C7H5O3.C5H6N2
Crystal Growth & Design (2009) 9, 3 1546
a=11.9491(13)Å b=9.0539(10)Å c=11.1731(12)Å
α=90.00° β=115.0780(10)° γ=90.00°
3-Aminopyridinium 3,5-dihydroxybenzoate (3,5-dihydroxybenzoic acid)
2(C7H6O4).C5H7N2
Crystal Growth & Design (2009) 9, 3 1546
a=21.8769(11)Å b=11.7814(6)Å c=14.6796(7)Å
α=90.00° β=90.00° γ=90.00°
4-Aminopyridinium 3-hydroxybenzoate
C7H5O3.C5H7N2
Crystal Growth & Design (2009) 9, 3 1546
a=8.5521(8)Å b=12.7834(12)Å c=10.7993(11)Å
α=90.00° β=111.6490(10)° γ=90.00°
4-Aminopyridinium 3,5-dimethyl-4-hydroxybenzoate hydrate
C9H9O3.C5H7N2.H2O
Crystal Growth & Design (2009) 9, 3 1546
a=8.7720(9)Å b=12.1664(12)Å c=14.0288(14)Å
α=90.00° β=104.823(2)° γ=90.00°
3-Aminopyridinium 3,5-dihydroxybenzoate
C7H5O4.C5H7N2
Crystal Growth & Design (2009) 9, 3 1546
a=9.6416(15)Å b=10.5167(16)Å c=11.7845(19)Å
α=90.00° β=105.398(2)° γ=90.00°
4-Aminopyridinium 4-hydroxybenzoate hydrate
C7H5O3.C5H7N2.H2O
Crystal Growth & Design (2009) 9, 3 1546
a=7.4783(9)Å b=11.7306(13)Å c=14.2792(16)Å
α=87.677(2)° β=77.937(2)° γ=83.687(2)°
Pyridine-2,3,5,6-tetracarboxylic acid
C9H5NO8,2(H2O)
Crystal Growth & Design (2006) 6, 8 1753
a=5.5311(6)Å b=6.2566(7)Å c=9.0041(10)Å
α=70.187(2)° β=76.251(2)° γ=72.714(2)°
Pyridine-2,3,5,6-tetracarboxylic acid
C9H5NO8,2(H2O)
Crystal Growth & Design (2006) 6, 8 1753
a=5.5412(11)Å b=6.3763(13)Å c=9.0710(18)Å
α=110.23(3)° β=91.99(3)° γ=106.39(3)°
Pyridine-2,4,6-tricarboxylic acid
C8H5NO6,2(H2O)
Crystal Growth & Design (2006) 6, 8 1753
a=5.9452(12)Å b=9.4204(19)Å c=18.370(4)Å
α=90.00° β=90.00° γ=90.00°
3-amino-2-chloropyridine
C5H5ClN2
Crystal Growth & Design (2006) 6, 6 1278
a=6.446(5)Å b=8.022(6)Å c=11.991(8)Å
α=90.00° β=104.510(11)° γ=90.00°
2-bromo-3-hydroxypyridine
C5H4BrNO
Crystal Growth & Design (2006) 6, 6 1278
a=11.5563(12)Å b=12.7285(13)Å c=3.8875(4)Å
α=90.00° β=90.00° γ=90.00°
3-hydroxy-2-methylpyridine
C6H7NO
Crystal Growth & Design (2006) 6, 6 1278
a=11.053(2)Å b=9.6151(19)Å c=11.316(2)Å
α=90.00° β=100.64(3)° γ=90.00°
C6H4BrNO2
C6H4BrNO2
Crystal Growth & Design (2006) 6, 6 1278
a=3.8571(5)Å b=12.3235(15)Å c=12.5884(15)Å
α=90.00° β=90.00° γ=90.00°
3-Hydroxy-2-methylpyridine-N-oxide
C6H7NO2
Crystal Growth & Design (2006) 6, 6 1278
a=4.6258(9)Å b=10.3353(19)Å c=12.677(2)Å
α=90.00° β=99.270(3)° γ=90.00°
3-amino-2-bromopyridine
C5H5BrN2
Crystal Growth & Design (2006) 6, 6 1278
a=7.9689(5)Å b=13.1908(8)Å c=11.6096(7)Å
α=90.00° β=104.6860(10)° γ=90.00°
Olanzapinium hydrogenmalonate
C17H21N4S,C3H3O4
Crystal Growth & Design (2013) 13, 8 3672
a=9.1759(9)Å b=9.1769(9)Å c=13.6079(14)Å
α=92.146(2)° β=94.031(2)° γ=115.2640(10)°
Olanzapinium salicylate benzene
C33H35N4O3S
Crystal Growth & Design (2013) 13, 8 3672
a=9.270(4)Å b=10.539(5)Å c=15.713(7)Å
α=102.808(7)° β=104.176(8)° γ=95.930(8)°
Olanzapinium dimaleate monofumaric acid
C17H22N4S,(C4H4O4),2(C4H3O4)
Crystal Growth & Design (2013) 13, 8 3672
a=8.805(6)Å b=9.634(6)Å c=19.461(12)Å
α=88.035(11)° β=83.349(11)° γ=74.023(11)°
Olanzapinium p-aminobenzoate hemihydrate
C17H21N4S,C7H6NO2,O
Crystal Growth & Design (2013) 13, 8 3672
a=12.5118(10)Å b=9.6552(8)Å c=19.3403(16)Å
α=90.00° β=91.0660(10)° γ=90.00°
Olanzapine acetonitrile monohydrate
C17H20N4S,O
Crystal Growth & Design (2013) 13, 8 3672
a=24.549(2)Å b=12.5131(11)Å c=15.1433(13)Å
α=90.00° β=125.4670(10)° γ=90.00°
Olanzapine ethanol monohydrate
C17H20N4S,0.5(C2O),H2O
Crystal Growth & Design (2013) 13, 8 3672
a=24.541(7)Å b=12.459(3)Å c=15.178(4)Å
α=90.00° β=125.485(4)° γ=90.00°
Olanzapine acetone monohydrate
C17H20N4S,0.5(C3H6O),H2O
Crystal Growth & Design (2013) 13, 8 3672
a=24.628(3)Å b=12.5833(15)Å c=15.2002(18)Å
α=90.00° β=125.803(2)° γ=90.00°
1,4-di(bis(4'-hydroxyphenyl)methyl)benzene dimethylsulfoxide solvate
C32H26O4,2(C2H6OS)
New Journal of Chemistry (2010) 34, 4 623
a=11.0387(11)Å b=7.4017(7)Å c=19.4980(19)Å
α=90.00° β=96.343(2)° γ=90.00°
Glibenclamidesodium salt
C23H27ClN3NaO5S
CrystEngComm (2017) 19, 6 918
a=10.9425(10)Å b=10.1583(7)Å c=11.5023(11)Å
α=90° β=91.164(9)° γ=90°
4-(triphenylmethyl)benzoic acid, unsolvated form
C26H20O2
Journal of the Chemical Society, Perkin Transactions 2 (2000) 6 1223
a=7.390(2)Å b=15.477(2)Å c=33.858(2)Å
α=90.00° β=90.00° γ=90.00°
4-(triphenylmethyl)benzoic acid anisole clathrate
(C26H20O2).0.5(C7H8O)
Journal of the Chemical Society, Perkin Transactions 2 (2000) 6 1223
a=7.310(1)Å b=8.998(1)Å c=18.464(1)Å
α=89.98(1)° β=86.26(1)° γ=67.50(1)°
Hydantoin-5-propionic acid
C6H8N2O4
CrystEngComm (2015) 17, 28 5252
a=6.2475(4)Å b=7.1111(6)Å c=17.3692(11)Å
α=90.00° β=96.792(5)° γ=90.00°
Furosemide sodium salt trihydrate
C12H10ClN2O5SNa.3H2O
CrystEngComm (2014) 16, 22 4842
a=20.9184(10)Å b=10.4771(6)Å c=7.8468(4)Å
α=90.00° β=95.790(4)° γ=90.00°
Methyldiiodo sulfonylhydrazone
C20H16I2N2O2S
CrystEngComm (2014) 16, 22 4681
a=11.6335(16)Å b=11.6089(16)Å c=15.843(2)Å
α=90.00° β=96.670(2)° γ=90.00°
C6H6ClNO2S,C5H9NO
C6H6ClNO2S,C5H9NO
IUCrJ (2015) 2, 4 389-401
a=25.701(4)Å b=6.8096(4)Å c=19.177(3)Å
α=90.00° β=127.40(2)° γ=90.00°
Triethyl isocyanurate
C9H15N3O3
Acta Crystallographica Section C (1998) 54, 1 86-89
a=7.835(2)Å b=8.1440(10)Å c=16.820(5)Å
α=90.00° β=90.00° γ=90.00°
17-Ethylenedioxyandrost-4-ene-3,6-dione
C21H28O4
Acta Crystallographica Section C (1998) 54, 12 1894-1898
a=8.162(2)Å b=9.919(2)Å c=22.021(4)Å
α=90.00° β=90.00° γ=90.00°
C20H16Br2N2O2S,0.5(C6H6)
C20H16Br2N2O2S,0.5(C6H6)
Crystal Growth & Design (2007) 7, 10 2047
a=8.0184(8)Å b=11.9872(12)Å c=13.5855(13)Å
α=112.826(2)° β=106.592(2)° γ=93.964(2)°
C22H22N2O2S
C22H22N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=22.0093(13)Å b=11.9763(7)Å c=15.1853(9)Å
α=90.00° β=100.9370(10)° γ=90.00°
C22H22N2O2S
C22H22N2O2S
Crystal Growth & Design (2007) 7, 10 2047
a=42.043(8)Å b=8.0381(16)Å c=12.345(3)Å
α=90.00° β=104.08(3)° γ=90.00°
Lornoxicam Ammonium salt
C13H13N4O4S2Cl
Crystal Growth & Design (2014) 14, 6 2945
a=7.5577(7)Å b=10.3747(9)Å c=12.0879(12)Å
α=68.516(9)° β=75.433(8)° γ=70.585(8)°
Lornoxicam
C13H10N3O4S2Cl
Crystal Growth & Design (2014) 14, 6 2945
a=7.2020(4)Å b=13.5420(8)Å c=14.9987(7)Å
α=90.00° β=90.00° γ=90.00°
Isoniazid-Caffeic acid
C9H8O4,C6H7N3O
Crystal Growth & Design (2014) 14, 11 5991
a=7.2470(12)Å b=20.694(4)Å c=9.6836(16)Å
α=90.00° β=100.974(3)° γ=90.00°
Sulfamethizole-bipyridine cocrystal
C9H10N4O2S2,C10H8N2
Crystal Growth & Design (2015) 15, 7 3498
a=8.1754(7)Å b=18.6120(10)Å c=13.1690(11)Å
α=90.00° β=93.048(7)° γ=90.00°
C11H10O4
C11H10O4
Journal of the American Chemical Society (1999) 121, 1936-1944
a=7.260(1)Å b=30.507(3)Å c=8.252(2)Å
α=90° β=90.724(9)° γ=90°
C9H7BrO2
C9H7BrO2
Journal of the American Chemical Society (1999) 121, 1936-1944
a=8.306(3)Å b=7.261(2)Å c=14.269(6)Å
α=90.0000° β=113.13(2)° γ=90.0000°
C13H10IN3O3
C13H10IN3O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=8.4419(17)Å b=12.987(3)Å c=12.399(3)Å
α=90.00° β=96.59(3)° γ=90.00°
DMF solvate of N-(4-cyanophenyl)-N'-(4-nitrophenyl)urea
C14H10N4O3,C3H7NO
Crystal Growth & Design (2007) 7, 12 2675-2690
a=7.9488(7)Å b=10.4797(9)Å c=11.9563(10)Å
α=114.6710(10)° β=95.441(2)° γ=101.2000(10)°
C15H13N3O4,C2H6OS
C15H13N3O4,C2H6OS
Crystal Growth & Design (2007) 7, 12 2675-2690
a=6.0509(6)Å b=12.4575(12)Å c=12.5937(11)Å
α=78.120(2)° β=82.891(2)° γ=80.105(2)°
C15H16N4O3
C15H16N4O3
Crystal Growth & Design (2007) 7, 12 2675-2690
a=6.0710(12)Å b=7.5613(15)Å c=31.715(6)Å
α=89.95(3)° β=87.01(3)° γ=85.23(3)°
1,3-bis(3-pyridyl)ureadihydrate
C11H10N4O,2(H2O)
Crystal Growth & Design (2006) 6, 1 161
a=6.7932(8)Å b=19.560(2)Å c=9.2746(11)Å
α=90.00° β=101.260(2)° γ=90.00°
C5H6N2O2S
C5H6N2O2S
Crystal Growth & Design (2012) 12, 9 4567
a=4.9893(9)Å b=7.0628(16)Å c=9.7308(16)Å
α=108.250(2)° β=94.716(3)° γ=96.499(3)°
Niclosamide-theophylline-acetonitrile solvate
C13H8Cl2N2O4,C7H8N4O2,C2H3N
Crystal Growth & Design (2012) 12, 9 4588
a=8.579(3)Å b=10.733(4)Å c=13.216(5)Å
α=105.579(6)° β=94.104(6)° γ=96.024(6)°
2,6-Dichloro-4-(diphenylmethylene)-cyclohexa-2,5-dienone
C19H12Cl2O
Crystal Growth & Design (2008) 8, 1 140
a=14.066(5)Å b=6.489(2)Å c=17.068(6)Å
α=90.00° β=97.853(7)° γ=90.00°
2,4,6-tris(4-iodophenoxy)-1,3,5-triazine, hexachlorobenzene
2(C21H12I3N3O3),C6Cl6
Crystal Growth & Design (2005) 5, 3 887
a=15.686(4)Å b=15.686(4)Å c=18.583(7)Å
α=90.00° β=90.00° γ=120.00°
C24H26N4O8S2
C24H26N4O8S2
Crystal Growth & Design (2011) 11, 5 1930
a=8.7426(8)Å b=5.2061(5)Å c=27.7269(19)Å
α=90.00° β=102.935(2)° γ=90.00°
C13H12N2O2
C13H12N2O2
Crystal Growth & Design (2011) 11, 10 4594
a=11.038(10)Å b=9.067(8)Å c=11.392(10)Å
α=90.00° β=101.860(14)° γ=90.00°
Pyrogallol
C6H6O3
Crystal Growth & Design (2012) 12, 8 3944
a=12.1144(11)Å b=3.7765(3)Å c=13.1365(12)Å
α=90.00° β=115.4840(10)° γ=90.00°
C36H38N4O13
C36H38N4O13
Crystal Growth & Design (2012) 12, 10 4963
a=33.756(5)Å b=7.1890(11)Å c=14.479(2)Å
α=90.00° β=106.874(16)° γ=90.00°
C13H15N3O5
C13H15N3O5
Crystal Growth & Design (2013) 13, 4 1551
a=6.750(2)Å b=7.060(2)Å c=14.809(4)Å
α=95.977(4)° β=97.899(5)° γ=104.722(4)°
C13H11N3O4S2,C2H4O2
C13H11N3O4S2,C2H4O2
Crystal Growth & Design (2013) 13, 5 1988
a=10.482(4)Å b=8.811(3)Å c=19.127(10)Å
α=90.00° β=99.38(4)° γ=90.00°
C13H11N3O4S2,CH2O2
C13H11N3O4S2,CH2O2
Crystal Growth & Design (2013) 13, 5 1988
a=12.080(3)Å b=14.546(3)Å c=9.954(2)Å
α=90.00° β=110.05(3)° γ=90.00°
C13H11N3O4S2,HCl
C13H11N3O4S2,HCl
Crystal Growth & Design (2013) 13, 5 1988
a=10.6360(18)Å b=15.312(3)Å c=10.4996(18)Å
α=90.00° β=116.543(2)° γ=90.00°
C12H32N2O8S2
C12H32N2O8S2
Crystal Growth & Design (2013) 13, 4 1752
a=12.239(3)Å b=15.151(3)Å c=5.2980(11)Å
α=90.00° β=90.00° γ=90.00°
C28H58N4O13
C28H58N4O13
Crystal Growth & Design (2013) 13, 4 1752
a=8.5813(6)Å b=10.5252(8)Å c=10.9210(8)Å
α=70.6260(10)° β=68.8720(10)° γ=73.8670(10)°
2-chloro-3-hydroxypyridine-N-oxide
C5H4ClNO2
Crystal Growth & Design (2006) 6, 6 1278
a=11.2712(14)Å b=12.7754(16)Å c=3.7794(5)Å
α=90.00° β=90.00° γ=90.00°
3-hydroxypyridine-N-oxide
C5H5NO2
Crystal Growth & Design (2006) 6, 6 1278
a=6.3536(8)Å b=6.5014(8)Å c=6.9499(8)Å
α=113.794(2)° β=99.650(2)° γ=106.930(2)°